Sophia Genetics
Sophia Genetics Q1 Revenues Climb 13 Percent, Beat Wall Street Estimate
The company continued to bring in new customers and grew analyses on its Sophia DDM platform by 11 percent year over year.
OncoHelix, AstraZeneca Canada Partner to Provide Prostate Cancer Liquid Biopsy Testing
The Canadian lab will assay patients' blood samples using a test developed by Memorial Sloan Kettering and commercialized as a kit in partnership with Sophia Genetics.
Sophia Genetics Q4, FY24 Revenues Rise 4 Percent on Analysis Growth, New Customers
The firm performed 352,000 analyses with its Sophia DDM platform and signed 92 customers in 2024, including 34 new users of its MSK ACCESS liquid biopsy application.
Sophia Genetics Q3 Revenues Fall 3 Percent
Expected softness in its biopharma customer segment was buoyed by record analysis volume for its Sophia DDM genomic analysis software platform.
Sophia sponsored a meeting gathering early adopters, pharma partners, and others to discuss the recently launched MSK-ACCESS, and soon-to-launch MSK-IMPACT kits.